Ironwood Pharma (IRWD) Reports Q2 Loss Per Share of 34c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Ironwood Pharmaceuticals Provides Second Quarter 2015 Investor Update
August 5, 2015 4:01 PM EDTLINZESS® (linaclotide) U.S. net sales of $112.1 million in second quarter 2015
Total LINZESS prescriptions increased approximately 56% in second quarter 2015 compared to second quarter 2014
Advanced innovative pipeline, including positive top-line Phase I data with sGC stimulator IW-1973
Entered agreement with Allergan to co-promote VIBERZI (eluxadoline) for IBS-D
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ironwood Pharmaceuticals,... More
